These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 10949699)

  • 1. [Anti-aldosterone: the evidence of the RALES study].
    Zannad F
    Arch Mal Coeur Vaiss; 2000 Jun; Spec No():8-9, 15. PubMed ID: 10949699
    [No Abstract]   [Full Text] [Related]  

  • 2. [Anti-aldosterone therapy in severe heart failure].
    van Guldener C; Donker AJ
    Ned Tijdschr Geneeskd; 1999 Aug; 143(34):1724-6. PubMed ID: 10494316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Value of diuretics and aldosterone antagonists in the treatment of heart failure].
    Schwinger RH
    Dtsch Med Wochenschr; 1999 Sep; 124 Suppl 2():S40-7. PubMed ID: 10535046
    [No Abstract]   [Full Text] [Related]  

  • 4. Aldosterone blockade in heart failure.
    Struthers AD
    J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5 Suppl 1():S23-7. PubMed ID: 15526239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Blocking of aldosterone receptors reduces the risk of events in patients with severe cardiac failure].
    Opasich C
    Ital Heart J Suppl; 2000 Mar; 1(3):425-6. PubMed ID: 10815276
    [No Abstract]   [Full Text] [Related]  

  • 6. [Guidelines for diagnosis and treatment of heart failure].
    Société européene de cardiologie
    Arch Mal Coeur Vaiss; 2002 Feb; 95 Spec 2(5 Spec 2):5-53. PubMed ID: 11933547
    [No Abstract]   [Full Text] [Related]  

  • 7. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
    Bauersachs J; Fraccarollo D
    Minerva Cardioangiol; 2003 Apr; 51(2):155-64. PubMed ID: 12783071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
    McMurray JJ; Pfeffer MA; Swedberg K; Dzau VJ
    Circulation; 2004 Nov; 110(20):3281-8. PubMed ID: 15545527
    [No Abstract]   [Full Text] [Related]  

  • 10. Cellular basis for therapeutic choices in heart failure.
    Opie LH
    Circulation; 2004 Oct; 110(17):2559-61. PubMed ID: 15505109
    [No Abstract]   [Full Text] [Related]  

  • 11. An old drug provides surprising benefits for heart-failure patients.
    Harv Heart Lett; 1999 Dec; 10(4):5-7. PubMed ID: 10564892
    [No Abstract]   [Full Text] [Related]  

  • 12. New strategies for treatment of heart failure with aldosterone antagonists and the risk of hyperkalaemia.
    Cruz CS; Cruz LS; Domingues GS; Souza CA
    Expert Opin Drug Saf; 2005 Jul; 4(4):677-88. PubMed ID: 16011447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spironolactone in severe heart failure: enhances efficacy of diuretic + ACE inhibitor combinations.
    Prescrire Int; 2000 Oct; 9(49):158-9. PubMed ID: 11603418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker.
    Chrysostomou A; Pedagogos E; MacGregor L; Becker GJ
    Clin J Am Soc Nephrol; 2006 Mar; 1(2):256-62. PubMed ID: 17699214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of aldosterone antagonism in heart failure: pharmacotherapeutic options].
    Diercks GF; Overdiek JW; van Veldhuisen DJ
    Ned Tijdschr Geneeskd; 2001 Feb; 145(5):204-8. PubMed ID: 11219145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conclusions on the management of heart failure.
    Swedberg K
    J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5 Suppl 1():S34-6. PubMed ID: 15526241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor.
    Ogawa S; Takeuchi K; Mori T; Nako K; Ito S
    Clin Exp Pharmacol Physiol; 2006; 33(5-6):477-9. PubMed ID: 16700881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure.
    Lenzen MJ; Boersma E; Reimer WJ; Balk AH; Komajda M; Swedberg K; Follath F; Jimenez-Navarro M; Simoons ML; Cleland JG
    Eur Heart J; 2005 Dec; 26(24):2706-13. PubMed ID: 16183692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Registry of heart failure patients hospitalized in 2000. Data from the National College of Cardiology and General Hospital].
    Dujardin JJ; Hanania G; Mialet G; Bounhoure JP; Gallois H
    Arch Mal Coeur Vaiss; 2002 Feb; 95 Spec 4(5 Spec 4):7-10. PubMed ID: 11933561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
    Azadpour M; Lamas GA
    Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):891-902. PubMed ID: 15500434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.